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Length of OS was defined as the time between initial confirmatory diagnosis of aPXA and date 109 of death or last known date of follow-up. 110
All patient information was compiled into a single Microsoft® Excel database. Patient 111 data was analyzed by gender, age, race, length of survival, and mortality. Tumor data was 112 analyzed by size, location, recurrence, metastasis, and pathological features including mitotic 113 index and necrosis. Treatment data was analyzed by modality including EOR, use of adjuvant 114 radiotherapy, use of Gamma Knife™ radiosurgery, and the amount of radiation received. 115
Patients were excluded if their original pathology slides were unavailable for re-116 confirmation of diagnosis, or if they lacked comprehensive clinical information including 117 presenting symptoms, tumor characteristics, treatment modality, disease recurrence, and dates of 118 follow-up. 119
Pathologic Determination of Grade 120
Histopathological diagnosis of aPXA was independently confirmed by 3 senior 121 neuropathologists (AP, AB, TT). Tumors were classified specifically as aPXA only upon 122 agreement of 2 of 3 senior neuropathologists, with ambiguous cases excluded from our series to 123 preclude the possibility of including misidentified tumors. Of ten patients initially identified with 124 possible aPXA, 2 patients were excluded due to uncertainty over final diagnosis. Tumors were 125
identified as aPXA if they demonstrated nuclear and cytoplasmic pleomorphism, xanthomatous 126 astrocytic cells, multi-nucleated giant cells, and significant mitotic activity, defined as 5 or more 127 mitoses per 10 hpf, and/or the presence of necrosis. 128
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Patient Population and Tumor Characteristics 131
The UCSF Department of Neurosurgery managed 8 patients with aPXA from 1999-2012 132 (Table 1) . There was a female predominance in our cohort, with 5 female and 3 male patients. 133
Our patients ranged in age from 4 to 74 years at time of diagnosis, with median and mean ages of 134 22 and 28, respectively. Tumor volumes averaged 61 cm 3 , with a diameter ranging from 0.9 cm 135 to 6.3cm. The most common presenting symptoms were seizure (50%) and headaches (25%). 136
The great majority of aPXAs arose from the cerebral hemispheres, including the frontal (38%) 137 and temporal (50%) lobes, with one tumor arising in the posterior fossa (13%). Two tumors 138 (25%) were located in eloquent cortex, including the left supplementary motor area and the left 139
frontotemporal lobes 140
Histopathology 141
The histopathologic characteristics of our patient cohort are summarized in Table 1 Similar to other published series, our patients, with a median age of 22, tended to be 171 younger than those with high-grade glioma. They also predominately developed tumors in the 172 frontotemporal lobes, resulting in a majority of patients presenting with seizures (50%). Our 173 experience, however, does also point to the fact that aPXA is not simply a diagnosis of children 174 and young adults, as 4 of 8 (50%) patients were older than 30. Additionally, while PXA isM A N U S C R I P T PXA and aPXA patients. Their analysis revealed that GTR was better than STR in prolonging 197 PFS -but not OS -in PXA patients. However, they were unable to draw substantial conclusionsM A N U S C R I P T
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9 from the literature about outcome predictors among aPXA patients. 33 Thus, the role of EOR 199 remains controversial. 200
In our series, of the 2 aPXA patients who underwent GTR, one suffered from recurrence. 201
The remaining 6 patients with STR suffered from progression. Nevertheless, given the small 202 sample size of our study, it is difficult to derive conclusions on whether GTR offers patients the 203 best means of tumor control. Similarly, the utility of adjuvant therapy remains questionable: of 204 the 4 patients who received postoperative XRT or chemotherapy, only 50% were alive by the end 205 of the study. This observation is further strengthened by the finding that adjuvant therapies were 206 completely ineffective in preventing residual tumor from progressing in patients who underwent 207 STR. As such, unless the risk of morbidity is unacceptably high, we would thus advocate for 208 aggressive EOR especially in cases where frozen intraoperative pathology is concerning for 209
aPXA. Given that current therapies appear inadequate for preventing dissemination, reduction of 210 initial tumor burden may also have prohibitive effects on future development of tumor spread 211 throughout the CNS, though this remains speculation and would benefit from further study. 212
Examination of treatment strategies and clinical courses for aPXA patients suggests that 213 the presence or absence of anaplastic features is not simply a pathologic distinction, but a feature 214 that results in divergent patient outcomes. In our series, poor clinical outcomes were associated 215 with aPXA. About 50% of our aPXA patients showed evidence of tumor dissemination, with 4 216 patients suffering leptomeningeal, intraparenchymal, and spinal drop metastases. In one of the 217 few other studies stratifying clinical outcomes based on PXA and aPXA pathology, Vu and 218 colleagues reported aPXA recurrence-free survival of 53% and OS of 82.3% at 1 year, with 219 recurrence-free survival of 33% and OS of 50% at 5 years.
33 For PXA, they report a 5-year 220 survival rate of 81-86%, and a recurrence-free survival rate of 49-72%. 7, 8, 33 Other studies 221 M A N U S C R I P T
examining the significance of anaplastic features on patient outcomes additionally note their 222 association with poor prognosis. Tumor mitoses and necrosis have each been associated with 223 worsened OS, 6, 7, [33] [34] [35] and mitotic activity has been associated with earlier recurrence and poorer 224 survival even when accounting for EOR. 7 In one such study, 9 of 15 deaths were noted to be 225 associated with the presence of histological necrosis. Given the unclear role for adjuvant radiation and chemotherapy, 5, 8, 10, 11, [36] [37] [38] [39] efforts are 238 increasingly underway to understand the unique tumor biology of PXA, including a greater 239 emphasis on molecular markers. Despite sharing an astrocytic background, it appears that PXA 240 and aPXA do not frequently possess MGMT methylation, leading one group of investigators to 241 raise doubts about the benefits of temozolomide chemotherapy for PXA. Other scattered case 242 reports note some success with chemotherapy with carboplatin and vincristine for 2 patients with 243 aPXA. 37, 40 Larger series have been unable to determine a role, if any, for chemotherapy. 7, 33, 38 244 M A N U S C R I P T
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Further study of cancer markers have validated the unique genetic background of PXA. In 245 several analyses of the presence of TP53 mutations, only 6% of all cases (7 of 123) were found 246 to be positive for the mutation, and amplificiations of EGFR, MDM2, and CDK4 also appear to 247 be absent. [41] [42] [43] Interestingly, BRAF V600E appears to be a common mutation among PXA, with 248 several groups suggesting it be used as a molecular and diagnostic marker for PXA given its 249 frequency of ~60% of the tumors studied and absence in high grade glioma and meningeal 250 tumors. 44, 45 The mutation has been shown to promote cell proliferation, differentiation, and 251 survival via the RAS/RAF/MEK/ERK kinase pathway. 44 We examined the mutation among our 252 aPXA population and found a slightly lower prevalance of 38%. Given the availability of agents 253 that target BRAF such as PLX-4032 and HSP90 inhibitors, aPXAs may be candidates for such 254 biologic therapy, offering an important new treatment modality, particularly in lesions 255 unamenable to further surgery or unresponsive to radiotherapy and/or chemotherapy. 256
Study Strengths and Limitations 257
Our study contains only 8 patients and is retrospective, thus precluding meaningful 258 multivariate analysis and may contain selection bias. Additionally, the variable length of follow-259 up data make it difficult to draw conclusions on best treatment strategies and outcomes, 260 underscoring the importance of multi-institutional efforts to publish data on this rare tumor. 261 Furthermore, our BRAF V600E prevalence may underestimate the true rate given increasing 262 awareness and nonuniform testing for this alteration in aPXA. Finally, our clinical and tumor 263 information was limited by only half our cohort having available data on tumor size. 
